Reducing Drug Development Costs with Protocol Cost Savings Analysis (PCSA)

摘要

Continuing increases in the cost of clinical research are driving industry-wide efforts to reduce costs, or to at least slow the increases. Many of these efforts are complex, expensive, time-consuming or risky to implement, or can diminish quality or damage the sponsor’s (or CROs) relationships with investigational sites. All the while, many sponsors are leaving money on the table that is hiding in plain sight: third-party reimbursements for the costs of tests and procedures that can be deemed “routine care.”